Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1597

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of Duloxetine Hydrochloride, showing its molecular structure with key atoms and bonds including a thiophene ring and bicyclic aromatic system.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time between placebo and duloxetine delayed-release capsules. The x-axis represents time, and the y-axis shows the proportion of patients relapsing, with two lines indicating different treatment groups.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier survival curve comparing time to relapse (in days) between patients treated with Duloxetine delayed-release capsules and those given a placebo. The y-axis shows the proportion of patients with relapse, with Duloxetine represented by a solid line and placebo by a dashed line, illustrating relapse rates over approximately 250 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. Four lines compare Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo groups over varying pain improvement percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: DULOXETINE HYDROCHLORIDE 80 mg twice daily (BID), 80 mg once daily (QD), and placebo, with the vertical axis representing the percentage of patients improved and the horizontal axis showing percent improvement increments from greater than 0 to 100.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph illustrates treatment groups' efficacy in pain improvement over a range of improvement percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph showing the percentage of patients improved compared to percent improvement in pain from baseline. Four lines compare Duloxetine hydrochloride doses of 20 mg, 60 mg, and 120 mg once daily with a placebo group over varying levels of pain improvement percentage.*

FDA Label Image

Figure 7 (Duloxetine 08)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. It compares results between Duloxetine 60 mg once daily and placebo groups over a range of pain improvement percentages. The Duloxetine group shows higher patient improvement across the spectrum compared to placebo. Footnotes indicate measurement by the Brief Pain Inventory and dosing details for Duloxetine delayed-release capsules.*

FDA Label Image

Figure 8 (Duloxetine 09)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for two groups: placebo and Duloxetine Delayed-Release 60/120 mg once daily. The x-axis shows percent improvement in pain from 0% to 100%, and the y-axis shows percentage of patients improved from 0% to 100%. The Duloxetine group shows consistently higher patient improvement percentages compared to placebo.*

FDA Label Image

Figure 9 (Duloxetine 10)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for placebo and DUL 60 mg once daily. The graph shows two lines: one for placebo and one for DUL 60 mg, indicating patient improvement trends across different pain improvement percentages.*

FDA Label Image

Figure 10 (Duloxetine 11)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline, showing data for placebo and Duloxetine 60/120 mg once daily. The graph illustrates that patients taking Duloxetine have higher improvement percentages across various pain improvement levels compared to placebo.*

FDA Label Image

Label (Lbl721621597)

Label for Duloxetine Delayed-Release Capsules, USP 20 mg, containing 90 capsules. The label includes the NDC number 72162-1597, storage instructions, and manufacturer information indicating the product is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Towa Pharmaceutical Europe, S.L.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.